ArticleJournal of cellular and molecular medicine2025
The Key Role of COA6 in Pancreatic Ductal Adenocarcinoma: Metabolic Reprogramming and Regulation of the Immune Microenvironment.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Multi-omics analysis identifies CKLF as a promoter for HCC progression by regulating the AKT, ERK pathways, and infiltrating immune cells.Translational oncology · 2026Article
- Single-cell atlas reveals the key role of pro-inflammatory IREB2⁺ microglia subsets in the microenvironment of Alzheimer's disease.Clinical and experimental medicine · 2026Article
- Inflammation-associated immune-related genes as potential biomarkers for the diagnosis of interstitial cystitis.Clinical and experimental medicine · 2026Article
- Immune-Mitochondrial Crosstalk in Pancreatic Adenocarcinoma: Systematic Identification of Prognostic Biomarkers Through Immune Dictionary FrameworkEndocrine, metabolic & immune disorders drug targets · 2026Article
- Decoding the role of macrophage LAP3 in lung cancer - integration of single-cell technologies and machine learning reveals an orchestrating immunometabolic circuit at the tumor-epithelial interface.Frontiers in immunology · 2026Article
- A bibliometric study on microenvironment-mediated drug resistance in interventional liver cancer treatment.Discover oncology · 2025Article
- The Key Role of COA6 in Pancreatic Ductal Adenocarcinoma: Metabolic Reprogramming and Regulation of the Immune Microenvironment.Journal of cellular and molecular medicine · 2025Article
- Advances in the immunological microenvironment and immunotherapy of bladder cancer.Frontiers in immunology · 2025Review
- Single-cell transcriptomics reveals a novel mechanism of RDH16 regulating immune infiltration in hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application.Frontiers in immunology · 2025Review
- Roles of tumor-associated macrophages in triple-negative breast cancer progression.Frontiers in immunology · 2025Review
- Dendritic cell-related gene signature in pancreatic cancer stratifies patient subtypes and implicates a KCTD14-TNF signaling axis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterised by immune hypo-responsiveness due to its complex, immunosuppressive tumour microenvironment (TME). Mitochondrial metabolic reprogramming allows PDAC cells to shift between glycolysis and oxidative phosphorylation (OXPHOS), supporting energy production and cellular viability, thus promoting tumour progression and therapeutic resistance. Mitochondrial genes associated with PDAC were identified using SMR/HEIDI analysis combined with MRC IEU OpenGWAS and GTEx V8 pancreatic eQTL databases. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics were used to explore cellular interactions and construct spatial interaction networks. Potential small-molecule compounds targeting the TME were identified through drug prediction and molecular docking. COA6 expression was silenced in SW1990 and PANC-1 cells to assess effects on cell proliferation, migration, invasion and apoptosis. COA6, a key gene in the OXPHOS pathway, was upregulated in PDAC tumours compared to normal tissues. Functional assays showed that COA6 overexpression enhanced proliferation, migration and chemoresistance of PDAC cells. COA6 modulates OXPHOS, influences the TME and promotes drug resistance in PDAC. It is a promising therapeutic target for improving clinical outcomes in PDAC patients. Further research is needed to develop COA6-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.